{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T09:07:28Z","timestamp":1794474448418,"version":"4.9.1"},"reference-count":31,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"33","license":[{"start":{"date-parts":[[2022,8,19]],"date-time":"2022-08-19T00:00:00Z","timestamp":1660867200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,8,19]]},"abstract":"<jats:sec>\n            <jats:title>Rationale:<\/jats:title>\n            <jats:p>SAPHO syndrome is a rare clinical entity characterized by a wide range of dermatological and musculoskeletal manifestations. Treatment strategies are not standardized. Palmoplantar pustulosis (PPP) is the most common rash in patients with SAPHO syndrome.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Patient concerns:<\/jats:title>\n            <jats:p>A 24-year-old Chinese woman with no relevant medical or familial history had a 1-year history of cutaneous lesions with PPP and pain in the sternoclavicular joint.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Diagnosis:<\/jats:title>\n            <jats:p>Based on the diagnostic criteria for SAPHO syndrome proposed by Nguyen et al in 2012, we diagnosed SAPHO syndrome with severe PPP as the predominant manifestation.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Interventions:<\/jats:title>\n            <jats:p>Due to the limited therapeutic efficacy of methotrexate and cyclosporin, we started therapy with subcutaneous secukinumab 150\u2009mg weekly for the first month, then 150\u2009mg monthly thereafter.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Outcomes:<\/jats:title>\n            <jats:p>After 4 weeks of secukinumab administration, the patient showed significant remission of pustular skin lesions, with almost no joint pain and no adverse reaction. Complete remission of skin symptoms was achieved after 3 months. Joint pain and adverse events have not reoccurred in follow-up thus far.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions:<\/jats:title>\n            <jats:p>In patients with SAPHO syndrome, we recommend personalized treatment, which may have excellent therapeutic efficacy in those with PPP or severe skin symptoms. Although data related to the use of IL-17 blockers for SAPHO syndrome are very limited, secukinumab provides a novel therapeutic option, especially for patients with PPP and severe skin lesions. Further prospective studies are needed to support our findings.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/md.0000000000030065","type":"journal-article","created":{"date-parts":[[2022,8,19]],"date-time":"2022-08-19T13:15:09Z","timestamp":1660914909000},"page":"e30065","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":13,"title":["Exceptional response of skin symptoms to secukinumab treatment in a patient with SAPHO syndrome: Case report and literature review"],"prefix":"10.1097","volume":"101","author":[{"given":"Qiang","family":"Ji","sequence":"first","affiliation":[{"name":"First Clinical Medical College, Shandong University of Traditional Chinese Medicine, Jinan, Shandong, China"},{"name":"Department of Rheumatology and Autoimmunology, Shandong Provincial Qianfoshan Hospital, First Clinical Medical College, Shandong University of Traditional Chinese Medicine, Shandong Key Laboratory of Rheumatic Disease and Translational medicine, Shandong medicine and Health Key Laboratory of Rheumatism"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qing","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Autoimmunology, The First Affiliated Hospital of Shandong First Medical University & Shandong Provincial Qianfoshan Hospital, Shandong Key Laboratory of Rheumatic Disease and Translational medicine, Shandong medicine and Health Key Laboratory of Rheumatism."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenping","family":"Pan","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Autoimmunology, The First Affiliated Hospital of Shandong First Medical University & Shandong Provincial Qianfoshan Hospital, Shandong Key Laboratory of Rheumatic Disease and Translational medicine, Shandong medicine and Health Key Laboratory of Rheumatism."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanfeng","family":"Hou","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Autoimmunology, The First Affiliated Hospital of Shandong First Medical University & Shandong Provincial Qianfoshan Hospital, Shandong Key Laboratory of Rheumatic Disease and Translational medicine, Shandong medicine and Health Key Laboratory of Rheumatism."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiuhua","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Autoimmunology, The First Affiliated Hospital of Shandong First Medical University & Shandong Provincial Qianfoshan Hospital, Shandong Key Laboratory of Rheumatic Disease and Translational medicine, Shandong medicine and Health Key Laboratory of Rheumatism."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Bian","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Autoimmunology, The First Affiliated Hospital of Shandong First Medical University & Shandong Provincial Qianfoshan Hospital, Shandong Key Laboratory of Rheumatic Disease and Translational medicine, Shandong medicine and Health Key Laboratory of Rheumatism."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0379-6422","authenticated-orcid":false,"given":"Zhankui","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Autoimmunology, The First Affiliated Hospital of Shandong First Medical University & Shandong Provincial Qianfoshan Hospital, Shandong Key Laboratory of Rheumatic Disease and Translational medicine, Shandong medicine and Health Key Laboratory of Rheumatism."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20250504","first-page":"187","article-title":"Acne-pustulosis-hyperostosis-osteitis syndrome. Results of a national survey. 85 cases.","volume":"54","author":"Chamot","year":"1987","journal-title":"Rev Rhum Mal Osteoartic"},{"key":"R2-20250504","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1007\/s40257-020-00503-5","article-title":"palmoplantar pustulosis: recent advances in etiopathogenesis and emerging treatments.","volume":"21","author":"Misiak-Galazka","year":"2020","journal-title":"Am J Clin Dermatol"},{"key":"R3-20250504","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/j.semarthrit.2012.05.006","article-title":"The SAPHO syndrome.","volume":"42","author":"Nguyen","year":"2012","journal-title":"Semin Arthritis Rheum"},{"key":"R4-20250504","doi-asserted-by":"crossref","first-page":"381","DOI":"10.12688\/f1000research.52100.2","article-title":"Case report: PsAPSASH syndrome: an alternative phenotype of syndromic hidradenitis suppurativa treated with the IL-17A inhibitor secukinumab.","volume":"10","author":"Nikolakis","year":"2021","journal-title":"F1000Res"},{"key":"R5-20250504","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1007\/s10067-013-2251-1","article-title":"Diagnosing the SAPHO syndrome: a report of three cases and review of literature.","volume":"32","author":"Kundu","year":"2013","journal-title":"Clin Rheumatol"},{"key":"R6-20250504","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1093\/rheumatology\/keaa352","article-title":"Successful treatment of refractory mandibular lesions in SAPHO syndrome with secukinumab.","volume":"60","author":"Sun","year":"2021","journal-title":"Rheumatology (Oxford)"},{"key":"R7-20250504","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1016\/j.semarthrit.2018.04.003","article-title":"Biologics in SAPHO syndrome: a systematic review.","volume":"48","author":"Daoussis","year":"2019","journal-title":"Semin Arthritis Rheum"},{"key":"R8-20250504","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1016\/j.jbspin.2017.05.016","article-title":"IL-23\/Th17 targeted therapies in SAPHO syndrome. a case series.","volume":"84","author":"Wendling","year":"2017","journal-title":"Joint Bone Spine"},{"key":"R9-20250504","doi-asserted-by":"crossref","first-page":"953","DOI":"10.3899\/jrheum.201260","article-title":"Clinical and radiological remission of osteoarticular and cutaneous lesions in sapho patients treated with secukinumab: a case series.","volume":"48","author":"Wang","year":"2021","journal-title":"J Rheumatol"},{"key":"R10-20250504","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1016\/j.jaad.2019.01.066","article-title":"Secukinumab for moderate-to-severe palmoplantar pustular psoriasis: results of the 2PRECISE study.","volume":"80","author":"Mrowietz","year":"2019","journal-title":"J Am Acad Dermatol"},{"key":"R11-20250504","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1111\/j.1365-2133.2011.10233.x","article-title":"Management of palmoplantar pustulosis: do we need to change?","volume":"164","author":"Mrowietz","year":"2011","journal-title":"Br J Dermatol"},{"key":"R12-20250504","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.jdermsci.2020.03.003","article-title":"Palmoplantar pustulosis: current understanding of disease definition and pathomechanism.","volume":"98","author":"Murakami","year":"2020","journal-title":"J Dermatol Sci"},{"key":"R13-20250504","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1002\/art.1780341003","article-title":"The European spondylarthropathy study group preliminary criteria for the classification of spondylarthropathy.","volume":"34","author":"Dougados","year":"1991","journal-title":"Arthritis Rheum"},{"key":"R14-20250504","doi-asserted-by":"crossref","first-page":"199","DOI":"10.2174\/1871528113666140520100402","article-title":"Biological treatments for SAPHO syndrome: an update.","volume":"13","author":"Firinu","year":"2014","journal-title":"Inflamm Allergy Drug Targets"},{"key":"R15-20250504","doi-asserted-by":"crossref","DOI":"10.1136\/bcr-2012-007161","article-title":"Successful treatment of resistant SAPHO syndrome with anti-TNF therapy.","author":"Hampton","year":"2013","journal-title":"BMJ Case Rep"},{"key":"R16-20250504","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1111\/j.1365-2133.2007.07682.x","article-title":"Cutaneous side-effects in patients with rheumatic diseases during application of tumour necrosis factor-alpha antagonists.","volume":"156","author":"Lee","year":"2007","journal-title":"Br J Dermatol"},{"key":"R17-20250504","first-page":"1","article-title":"Secukinumab in the treatment of psoriasis and psoriatic arthritis: a review of the literature.","volume":"22","author":"Abrouk","year":"2017","journal-title":"Skin Therapy Lett"},{"key":"R18-20250504","doi-asserted-by":"crossref","first-page":"e000284","DOI":"10.1136\/rmdopen-2016-000284","article-title":"Update on interleukin-17: a role in the pathogenesis of inflammatory arthritis and implication for clinical practice.","volume":"3","author":"Miossec","year":"2017","journal-title":"RMD Open"},{"key":"R19-20250504","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1111\/jdv.12359","article-title":"Secukinumab improves hand, foot and nail lesions in moderate-to-severe plaque psoriasis: subanalysis of a randomized, double-blind, placebo-controlled, regimen-finding phase 2 trial.","volume":"28","author":"Paul","year":"2014","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"R20-20250504","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1056\/NEJMoa1412679","article-title":"Secukinumab inhibition of interleukin-17a in patients with psoriatic arthritis.","volume":"373","author":"Mease","year":"2015","journal-title":"N Engl J Med"},{"key":"R21-20250504","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1136\/annrheumdis-2012-202646","article-title":"Efficacy and safety of secukinumab, a fully human anti-interleukin-17A monoclonal antibody, in patients with moderate-to-severe psoriatic arthritis: a 24-week, randomised, double-blind, placebo-controlled, phase II proof-of-concept trial.","volume":"73","author":"McInnes","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"R22-20250504","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1016\/S0140-6736(15)61134-5","article-title":"Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial.","volume":"386","author":"McInnes","year":"2015","journal-title":"Lancet"},{"key":"R23-20250504","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.jaad.2015.04.011","article-title":"Secukinumab retreatment-as-needed versus fixed-interval maintenance regimen for moderate to severe plaque psoriasis: a randomized, double-blind, noninferiority trial (SCULPTURE).","volume":"73","author":"Mrowietz","year":"2015","journal-title":"J Am Acad Dermatol"},{"key":"R24-20250504","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/j.jaad.2015.05.013","article-title":"Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial.","volume":"73","author":"Tha\u00e7i","year":"2015","journal-title":"J Am Acad Dermatol"},{"key":"R25-20250504","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1111\/bjd.13348","article-title":"Secukinumab administration by pre-filled syringe: efficacy, safety and usability results from a randomized controlled trial in psoriasis (FEATURE).","volume":"172","author":"Blauvelt","year":"2015","journal-title":"Br J Dermatol"},{"key":"R26-20250504","doi-asserted-by":"crossref","first-page":"e14623","DOI":"10.1111\/dth.14623","article-title":"Retention and survival rate of etanercept in psoriasis over 15 years and patient outcomes during the COVID-19 pandemic: The real-world experience of a single center.","volume":"34","author":"Onsun","year":"2021","journal-title":"Dermatol Ther"},{"key":"R27-20250504","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1007\/s40264-019-00797-3","article-title":"Ustekinumab safety in psoriasis, psoriatic arthritis, and Crohn\u2019s disease: an integrated analysis of phase ii\/iii clinical development programs.","volume":"42","author":"Ghosh","year":"2019","journal-title":"Drug Saf"},{"key":"R28-20250504","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1111\/j.1365-2133.2010.09819.x","article-title":"Novel findings of Langerhans cells and interleukin-17 expression in relation to the acrosyringium and pustule in palmoplantar pustulosis.","volume":"163","author":"Hagforsen","year":"2010","journal-title":"Br J Dermatol"},{"key":"R29-20250504","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.jdermsci.2016.09.019","article-title":"Palmoplantar pustular psoriasis (PPPP) is characterized by activation of the IL-17A pathway.","volume":"85","author":"Bissonnette","year":"2017","journal-title":"J Dermatol Sci"},{"key":"R30-20250504","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1111\/jdv.12272","article-title":"Increased expression of IL-17A and limited involvement of IL-23 in patients with palmo-plantar (PP) pustular psoriasis or PP pustulosis; results from a randomised controlled trial.","volume":"28","author":"Bissonnette","year":"2014","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"R31-20250504","doi-asserted-by":"crossref","first-page":"389","DOI":"10.3109\/08916934.2014.906582","article-title":"TH17 cells are increased in the peripheral blood of patients with SAPHO syndrome.","volume":"47","author":"Firinu","year":"2014","journal-title":"Autoimmunity"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000030065","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,4]],"date-time":"2025-05-04T04:46:11Z","timestamp":1746333971000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000030065"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,19]]},"references-count":31,"journal-issue":{"issue":"33","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000030065","relation":{},"ISSN":["1536-5964"],"issn-type":[{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,19]]}}}